advanced, and there was mural thrombus in the aorta that partially occluded the ostia of both renal and common iliac arteries. The liver was of normal size (weighing 1530 g) with a smooth capsule and merely minor fatty change on slicing. The spleen weighed 430 g and was extremely soft. Both kidneys were enlarged, 180 g and 210 g. The external surfaces were slightly granular and on slicing the corticomedullary boundaries were blurred. There was no obstruction.
The duodenum and small intestine were normal. The whole of the colon showed multiple small polyps but no evidence of active ulcerative colitis or of neoplasm. There was an area of old infarction on the inferior surface of the occipital lobe of the brain-for which there was no clinical counterpart. There was atheroma in the cerebral arteries and in all the other arteries examined.
Microscopically the kidneys showed no evidence of chronic glomerulonephritis but there was severe amyloidosis (fig 2) that also affected all the organs examined. The inflammatory infiltration of the bowel was confined to the lamina propria; no granulomata were found-features in favour of ulcerative colitis rather than Crohn's disease. There was amyloid deposition around some small vessels in the bowel wall. The liver contained striking amyloid deposition around the arteries and veins: so did the spleen, heart, pancreas, lung, pituitary, and thyroid. Ratios as a warning of impending fetal deaths-A detailed study of the 57 fetal deaths that occurred in women with low ratios showed that 10 fetuses had serious congenital abnormalities, which included anecephaly in four cases. Thirteen other fetal deaths occurred before 32 weeks' gestation. In the remaining 34 cases there was no obvious reasons why these fetuses should not have had a good chance of survival. In eight of these cases abnormally low oestrogen :creatinine ratios persisted until fetal death occurred, whereas in 15 normal ratios gradually decreased to abnormally low levels at the time of fetal death. This decrease took place over at least one week in all patients except in the one postmature pregnancy, in which there was a sudden drop in the ratio over a period of one day accompanied by the loss of fetal heart sounds (fig 1) .
Need for frequent sequential assays-The oestrogen :creatinine ratio could not warn of fetal death in the 11 remaining cases of fetal death with a low ratio, because in eight of these the oestrogen:creatinine assay was requested after the loss of fetal heart sounds, and in three others the death occurred in one week between two assays. These three patients had abnormally low ratios at the time of fetal death, although the ratio had been normal a week before. More frequent assays, such as thrice a week, might have given a warning of impending fetal death in all these 11 cases, as they did in the 23 cases in which regular and frequent assays were carried out.
Live births after clinical intervention-In 59 patients whose oestrogen:creatinine ratios fell from normal to subnormal levels delivery after clinical intervention before the ratio decreased to below 3 resulted in a live infant in every case, including a set of twins. In many of these cases the reason for delivery was not necessarily a decrease in the ratio (fig 2) . 23 neonatal deaths, which, together with the 57 fetal deaths, gave a perinatal mortality of 425 0%. In the 5241 pregnancies with ratios above the fifth centile, there were 11 fetal deaths and 12 neonatal deaths. This gave a perinatal mortality of 0 44%, which is about 100 times less than that among those with low ratios (see table) .
There was also a highly significant difference in the perinatal mortality of babies under 2500 g between those with low ratios (38-7%) and those with normal ratios (6 0 %). Factors affecting ratio-There is a certain amount of day-to-day variability in the amount of oestrogen and creatinine measured-part of it owing to the chemical methods. 
Discussion
This assessment of the usefulness of the oestrogen:creatinine ratio in predicting fetal death is based on a study of the ratio in many patients over three and a half years. The results show that, barring unpredictable obstetric accidents such as abruptio placentae or intrapartum asphyxia, a normal oestrogen :creatinine ratio is associated with no danger to the life of the fetus, even in the presence of maternal disease such as severe hypertension and toxaemia, and may therefore be of some reassurance to the obstetrician. On the other hand, a decrease in the ratio from normal levels to below the fifth centile is very often associated with fetal death. The risk of fetal death in this high risk zone below the fifth centile is about 100 times that in pregnancies with higher ratios.
All the data on fetal deaths were obtained in cases where the obstetricians took no action on the basis of the oestrogen: creatinine ratio. Whenever the obstetricians did intervene before the ratio decreased to below the fifth centile no fetal deaths occurred. This decrease took place over several days and allowed sufficient time for clinical intervention. Clearly, also, as has been suggested,' weekly assays are not frequent enough to predict fetal death because a normal ratio might decrease to an abnormal one within one week, resulting in fetal death. Assays should therefore be carried out at least three times a week, and preferably daily, on all pregnant women.
Sequential assays are also essential because there is no significant difference in the mean oestrogen :creatinine ratio between normal and abnormal pregnancies, and only trends are of value in assessing fetoplacental function. Daily or even thrice-weekly assays on all patients would demand very large numbers of assays, and the need for a convenient method of sample collection and laboratory assay becomes obvious. The present method can provide an efficient daily service for many patients, as up to 400 assays can be performed by one technician in a working day. In addition, this method, which does not require 24-hour urine collection, can produce a result in less than 30 minutes after a request for an oestrogen assay. The lack of any sharp diurnal variation3 4 in the oestrogen: creatinine ratio makes it possible to confirm a downward trend in the ratio seen in a morning specimen by repeating the assay on a specimen collected in the afternoon of the same day. The ease of specimen collection, the large capacity of the fullyautomated method (60 samples per hour), and the low cost of reagents remove the practical limitations on the number of specimens that could be assayed using 24-hour collections. Thus the oestrogen: creatinine ratio could provide inexpensive but adequate antenatal care to those patients who cannot be seen often by an obstetrician.
This test may also be valuable in giving some idea of the quality of life' of the infant, as babies born to mothers who have low oestrogen excretion in pregnancy (in 24-hour collections) have a disproportionately higher incidence of neurological and other postnatal complications than those with normal oestrogen excretion.5 A follow-up study of all the small babies with normal or low oestrogen:creatinine ratios is in progress to test this expectation. Possibly mental retardation might be prevented by the early delivery of babies with poor fetoplacental function instead of allowing the pregnancies to continue to term. A patient who has had two mid-trimester abortions and no other pregnancies has had a normal hysterosalpingogram. Her first miscarriage was caused by abruptio placentae, and the second was probably associated with poor placentation, causing an intrauterine death. Could there be a common factor, and what further investigations should be undertaken to exclude any predisposing cause ?
Terms can confuse as much as they can clarify. This patient has evidence of failure of placental function, in the first instance acute, and in the second more chronic. It is highly likely that there is a common factor, but impossible with present knowledge to say what it might be. An association has been suggested between abruptio placentae and folic acid deficiency, operating in early pregnancy. The folic acid state might be investigated to decide if this substance might be given prophylactically, even before the next pregnancy. Generally, the results of further investigations to find predisposing causes for these intrauterine deaths are disappointing, though it is important not to overlook such obvious things as diabetes, renal disorder, syphilis, and rhesus incompatibility. More usually no overt causes will be found and the next pregnancy must be treated empirically, monitoring p4acental function and fetal growth closely and often, with recourse to periods of rest in bed in hospital. Depending on the woman herself and the depth of desire for a baby of her and her husband, a case can be made for her being in hospital for several months. It may or may not work but there is little else to offer, and if a third pregnancy also fails there is some merit in all concerned feeling that everything possible has been done.
It may minimise the inevitable psychological repercussions of such a personal tragedy.
I have used propanolol (Inderal) with success in a dose of 10 mg twice a day to stop excessive sweating in a patient who had athlete's foot. Is this a recognised use for this drug, and can it be used for other skin conditions where hyperhidrosis is present ?
Although Dale and Feldberg showed in 1934 that eccrine sweating was mediated through the orthosympathetic nervous system yet was parasympathetic-that is, cholinergic-in its pharmacological responsiveness, many authors have shown since 1948' that intradermal injections of adrenergic compounds also produce eccrine sweating. This is much less evident, however, than that induced by cholinergic substances. Several patients taking propanolol have observed diminished sweating, yet others have experienced increased sweating or were not aware of any appreciable change. Diminished sweating seems commoner with oxprenolol, but this is certainly not of the same order as that induced by the established antisweating drugs such as poldine methylsulphate. The cardiac and bronchial effects of betaadrenergic blocking agents, as well as other pharmacological considerations, argue against recommending this group of drugs to diminish excessive sweating.
